3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Non-Small-Cell Lung
2
Tongue Neoplasms
1
Salivary Gland Neoplasms
1
Recurrence
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lung Neoplasms
1
Klatskin Tumor
1
Cholangiocarcinoma
1
Carcinoma, Large Cell
1
Adenocarcinoma
1
Interventions
Gemcitabine
112
Cisplatin
76
Oxaliplatin
44
pembrolizumab
34
Fluorouracil
32
Capecitabine
30
durvalumab
27
Leucovorin
26
lenvatinib
23
Magnetic Resonance Spectroscopy
15
Irinotecan
14
Nivolumab
12
Biopsy
12
Albumin-Bound Paclitaxel
12
tislelizumab
11
Specimen Handling
11
Radiofrequency Ablation
11
Drug Therapy
11
pemigatinib
10
apatinib
10
Taxes
10
Floxuridine
10
130-nm albumin-bound paclitaxel
10
Radiotherapy
9
Bevacizumab
9
Platinum
8
Folfox protocol
8
Carboplatin
8
1,2-diaminocyclohexaneplatinum II citrate
8
tremelimumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cholangiocarcinoma
×
temoporfin
×
Clear all
NCT03003065
2023-08-22
PDT
Chinese University of Hong Kong
Phase 2
Completed
10 enrolled